BCLI - Brainstorm Cell Therapeutics Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.19
+0.03 (+0.95%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close3.16
Open3.17
Bid2.70 x 200
Ask3.30 x 700
Day's Range3.13 - 3.23
52 Week Range2.88 - 5.18
Volume24,876
Avg. Volume91,300
Market Cap60.108M
Beta2.07
PE Ratio (TTM)N/A
EPS (TTM)-0.31
Earnings DateMar 28, 2018 - Apr 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • MarketWatch2 days ago

    ALS patient group unhappy with how $115 million raised by the Ice Bucket Challenge is being spent

    Individuals with ALS say they aren’t benefiting from the Ice Bucket Challenge donations that poured into the nonprofit ALS Association.

  • PR Newswire13 days ago

    BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 7, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • PR Newswire14 days ago

    BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference

    HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 6, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • PR Newswire15 days ago

    BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 5, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the appointment of Anthony (Tony) Polverino, Ph.D., to its board of directors. Dr. Polverino is a highly accomplished senior biopharmaceutical executive with more than 25 years' industry experience in drug research and development. "We are honored to have Dr. Polverino join our board of directors," said Chaim Lebovits, president and chief executive officer of BrainStorm Cell Therapeutics.

  • PR Newswirelast month

    BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22

    HACKENSACK, N.J. and PETACH TIKVA, Israel , Jan. 16, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

  • Zacks Small Cap Research2 months ago

    BCLI: Receives GMP Certification for NurOwn® Manufacturing Facility; Ready to Seek Approval Under Hospital Exemption in Israel

    On January 3, 2018, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that the Israel Ministry of Health has granted Good Manufacturing Practice (GMP) certification for the contract manufacturing facility in Israel. The GMP certification is also recognized as equivalent to the EU GMP, thus BrainStorm could eventually seek approval under any expedited approval protocols in EU countries, although we believe this would not occur for an extended period of time.

  • PR Newswire2 months ago

    BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®

    HACKENSACK, N.J. and PETACH TIKVA, Israel, Jan. 3, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health (MoH) for its Israeli contract manufacturing facility.  The GMP certificate confirms the company's manufacturing site compliance with Israeli GMPs which are recognized as equivalent with EU GMP. This approval paves the way for the company's application to the Israel MoH for the treatment of ALS patients in Israel for a fee, under the newly introduced Hospital Exemption regulation.

  • PR Newswire2 months ago

    Brainstorm Issues 2017 Letter to Shareholders

    This past year was an extraordinary success for BrainStorm Cell Therapeutics. A key accomplishment was the enrollment of the first US patients in the Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). In addition to our clinical success, we have further developed our manufacturing capabilities in many ways, including validating the cryopreservation process.  Financially, we received additional non-dilutive grants from the California Institute for Regenerative Medicine (CIRM) as well as the Israel Innovation Authority.  In addition, we have further strengthened our executive team with new key appointments.

  • PR Newswire2 months ago

    BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase

    HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 20, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • PR Newswire3 months ago

    BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 29, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • PR Newswire3 months ago

    New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 9, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • PR Newswire4 months ago

    BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 2, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Eyal Rubin as Chief Financial Officer. Mr. Rubin will be responsible for all corporate finance and accounting activities for BrainStorm.

  • PR Newswire4 months ago

    BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 23, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • ACCESSWIRE4 months ago

    Corporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide

    Research Desk Line-up: Brainstorm Cell Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the ...

  • ACCESSWIRE4 months ago

    Featured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergan's Portfolio of Menin-MLL Inhibitors

    Research Desk Line-up: Brainstorm Cell Therapeutics Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 19, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines ...

  • Zacks Small Cap Research4 months ago

    BCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALS

    On October 16, 2017, BrainStorm (BCLI) announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of amyotrophic lateral sclerosis (ALS). The Phase 3 clinical trial is a randomized, double blind, placebo controlled, multi-dose trial that will take place at six leading ALS centers in the U.S. We anticipate approximately 200 patients being enrolled in the trial randomized 1:1 to NurOwn® or placebo. The company is focusing the trial on faster-progressing ALS patients since these patients demonstrated superior outcomes in the Phase 2 trial of NurOwn®.

  • PR Newswire4 months ago

    BrainStorm Announces Third Quarter 2017 Financial Results

    Conference Call with Management to Discuss Recent Corporate Progress at 8:30am Eastern Time Today HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 17, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics ...

  • ACCESSWIRE4 months ago

    Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q3 Earnings Call to be held October 17, 2017 at 8:30:00 ...

  • PR Newswire4 months ago

    BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

    HACKENSACK, N.J. and PETACH TIKVA, Israel, Oct. 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California. The patient population will be optimized to include the pre-specified subgroups who demonstrated superior outcomes in the NurOwn® Phase 2 ALS clinical trial. Top-line data are expected in 2019.

  • Reuters4 months ago

    BrainStorm enrolls first patients in advanced ALS stem cell trial

    BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California. The Phase 3 clinical trial is expected to include about 200 patients and will be conducted at six ALS clinical sites in the United States, Israel-based BrainStorm said on Monday. The company is developing a treatment made from adult stem cells for patients with ALS, a neuro-degenerative disease.

  • PR Newswire5 months ago

    Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17

    Conference Call and Live Webcast at 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 3, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of ...

  • PR Newswire5 months ago

    BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital

    HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase NYC at 4 PM EDT/ 1 PM PDT on September 27, 2017 at the Grand Hyatt 109 E 42nd St.  Ralph Z. Kern, MD MHSc, Chief Operating Officer and Chief Medical Officer will be presenting, as well as meeting with investors. Each company will be provided with a 30-minute time slot to present to an audience of investors and industry professionals and company management will also be available for one-on-one meetings with institutional investors. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased.

  • Zacks Small Cap Research6 months ago

    BCLI: Phase 3 Trial of NurOwn® to Initiate Soon

    On August 14 2017, BrainStorm (BCLI) announced financial results for the second quarter of 2017. As expected, the company did not report any revenue. The increase was due to an increase in payroll and stock-based compensation partially offset by a decrease in costs related to the U.S. clinical trial.

  • ACCESSWIRE6 months ago

    Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 16, 2017 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q2 Earnings Call to be held August 16, 2017 at 8:30 AM ...

  • PR Newswire6 months ago

    BrainStorm Announces Second Quarter 2017 Financial Results

    Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 15, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics ...